264 related articles for article (PubMed ID: 17211861)
1. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.
Park SH; Choi SJ; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Cho EK; Shin DB; Hoon Lee J
Cancer; 2007 Feb; 109(4):732-40. PubMed ID: 17211861
[TBL] [Abstract][Full Text] [Related]
2. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
Belani CP; Fossella F
Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
[TBL] [Abstract][Full Text] [Related]
3. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
5. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.
Kubota K; Watanabe K; Kunitoh H; Noda K; Ichinose Y; Katakami N; Sugiura T; Kawahara M; Yokoyama A; Yokota S; Yoneda S; Matsui K; Kudo S; Shibuya M; Isobe T; Segawa Y; Nishiwaki Y; Ohashi Y; Niitani H;
J Clin Oncol; 2004 Jan; 22(2):254-61. PubMed ID: 14722033
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy.
Lin CM; Chen CH; Chang JW; Tsao TC
Am J Clin Oncol; 2009 Apr; 32(2):169-73. PubMed ID: 19307958
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
[TBL] [Abstract][Full Text] [Related]
9. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan.
Chen YM; Perng RP; Shih JF; Tsai CM; Whang-Peng J
Lung Cancer; 2007 Jun; 56(3):363-9. PubMed ID: 17306906
[TBL] [Abstract][Full Text] [Related]
11. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial.
Ichinose Y; Yoshimori K; Sakai H; Nakai Y; Sugiura T; Kawahara M; Niitani H
Clin Cancer Res; 2004 Dec; 10(23):7860-4. PubMed ID: 15585618
[TBL] [Abstract][Full Text] [Related]
12. Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer.
Lai CL; Tsai CM; Chiu CH; Wang GS; Su WJ; Chen YM; Perng RP
Jpn J Clin Oncol; 2005 Dec; 35(12):700-6. PubMed ID: 16303792
[TBL] [Abstract][Full Text] [Related]
13. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
Aydiner A; Sen F; Saglam EK; Oral EN; Eralp Y; Tas F; Toker A; Dilege S
Clin Lung Cancer; 2011 Sep; 12(5):286-92. PubMed ID: 21729649
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
Kim YH; Kim JS; Choi YH; In KH; Park HS; Hong DS; Jeong TJ; Lee YY; Nam E; Lee SN; Lee KS; Kim HK
Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of a biweekly schedule of docetaxel and cisplatin in patients with metastatic non-small cell lung cancer.
Cho SH; Go SI; Lee GW; Kang JH; Kim HG; Kim SH; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS
Lung Cancer; 2010 Jul; 69(1):94-8. PubMed ID: 19796840
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L.
Abe T; Takeda K; Ohe Y; Kudoh S; Ichinose Y; Okamoto H; Yamamoto N; Yoshioka H; Minato K; Sawa T; Iwamoto Y; Saka H; Mizusawa J; Shibata T; Nakamura S; Ando M; Yokoyama A; Nakagawa K; Saijo N; Tamura T
J Clin Oncol; 2015 Feb; 33(6):575-81. PubMed ID: 25584004
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
Krug LM; Miller VA; Patel J; Crapanzano J; Azzoli CG; Gomez J; Kris MG; Heelan RT; Pizzo B; Tyson L; Sheehan C; Ross JS; Venkatraman E
Cancer; 2005 Nov; 104(10):2149-55. PubMed ID: 16208701
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer.
Teramoto K; Asada Y; Ozaki Y; Suzumura Y; Nakano Y; Sawai S; Tezuka N; Inoue S; Fujino S
Cancer Chemother Pharmacol; 2012 Oct; 70(4):531-7. PubMed ID: 22864949
[TBL] [Abstract][Full Text] [Related]
19. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
Schuette W; Nagel S; Blankenburg T; Lautenschlaeger C; Hans K; Schmidt EW; Dittrich I; Schweisfurth H; von Weikersthal LF; Raghavachar A; Reissig A; Serke M
J Clin Oncol; 2005 Nov; 23(33):8389-95. PubMed ID: 16293869
[TBL] [Abstract][Full Text] [Related]
20. A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer.
Kaira K; Tsuchiya S; Sunaga N; Yanagitani N; Watanabe S; Imai H; Hisada T; Ishizuka T; Saito R; Mori M
Am J Clin Oncol; 2007 Feb; 30(1):51-6. PubMed ID: 17278895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
